SHINE Technologies and Radiopharm Theranostics signed a clinical supply agreement, in which SHINE will supply Radiopharm with isotope non-carrier-added lutetium-177 (Lu-177), the company announced recently.

“One way or another, nearly everyone has been affected by cancer,” SHINE Therapeutics Division General Manager Chris Vessell said in a statement. “SHINE’s efforts in lutetium-177 are all about prolonging the lives of those affected most directly. We are excited that our isotopes will play a critical role in Radiopharm Theranostics’ programs that aim to revolutionize cancer treatment.”

According to a release, the isotope will be used by Radiopharm in the development of its clinical pipeline of diagnostic and therapeutic radiopharmaceutical products.

Radiopharm Theranostics is headquartered in Sydney, Australia.